ClinicalTrials.Veeva

Menu
S

Segal Trials | Behavioral Clinical Research, Inc.

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

SEP-363856
Buprenorphine
MK-8189
KarXT
STS101
MK-8189-008
Psilocybin
AEF0117
JZP150

Parent organization

This site is a part of Segal Trials

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

2 of 10 total trials

An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication

An Extension study to a clinical study that will continue to evaluate the effectiveness and safety of SEP-363856 in people with schizophrenia that sw...

Invitation-only
Schizophrenia
Drug: SEP-363856

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

Enrolling
Treatment Resistant Depression
Drug: Psilocybin

Trial sponsors

A
Akili Interactive Labs logo
C
Indivior logo
Jazz Pharmaceuticals logo
Karuna Therapeutics logo
Merck Sharp & Dohme (MSD) logo
Otsuka logo
S
Sumitomo Pharma logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems